to our XXXX and afternoon, like quarter good welcome everyone. second operator, you, you call. would Thank I conference to
accounting development transactions, of planning, served and brings science leadership welcome on extensive includes and in SEC experience XX several Financial Torsten of two in of capital Chief product Torsten Before decades was Officer raising, and I I Hombeck to to His began, corporate M&A team. biotech our companies. launch, aspects senior like expertise Dr. course, would positions reporting. having officially all life June experience senior over strategic and appointed at
capital million a financial before for after on the performance impact, remarks raise Board. successful we coming closing provide the Torsten He our $X.X made including up major a to already will call just open has of weeks related questions. later
Now this quarter. let our me of review a begin performance with
always, product second continues million of revenues became Officer. quarter XX% OvaSuite year-over-year growth $X.X compared second quarters quarter trend were representing the As the each of I our for of Executive XXXX. since with start for to quarterly established I’ll growth. the Chief of This growth
OvaWatch XX% total. in XX% XXXX. for The number adoption. XXXX ended in full tests of in OvaWatch compared the second X,XXX, an the OvaSuite quarter was XX, XXXX contributing second This same quarter the performed of represents an months an the period of second of to tests the performed versus increase of was tests with of quarter OvaSuite the increase increase performed XX,XXX, XX% to June tests XXX six
Florida by was territories in are Importantly, XXXX. substantially bear to focus and leaner improving rep renewed a This of women’s demonstrates like team along representative rep much field test per on BioReference the underperforming with in growth with to from per beginning to volume XXX unprofitable sales our that for XXXX year-to-date eliminating commitment driven volume partnerships care Laboratories a to fruit. XXX
I’m volume price, on look unit focus with our we very pleased progress. and When average beyond
to AUP $XXX. the OvaSuite for increased Our quarter
first $XXX Importantly, over we second the began unique OvaWatch the resulted billing X, quarter increase OvaWatch quarter. in of on which XXX% under PLA of Code its April AUP
days, see are for still we pleased with While reimbursement line we in are patterns nicely up OvaWatch early OvaXPlus. to
prepare EndoCheck test of portfolio, for launch while of strategy the second the XXXX. an end a OvaSuite half by at on as year successful possible is payer adoption that for the as of much launched aimed we making have We progress the OvaSuite
coverage local an of disclose future reimbursement to could reimbursement, and to events have national in participating changes CMS decisions. on any revenue. industry They’re in unfold diagnostic we’ll actively with CMS Medicare broadly and impact tests our that continue collaborate and More initiatives through with
terms commercial strategic last value and initial refining marketing which in The launched we summer. and field Lastly, sales of proposition sales overall of refresh, our the on stages the the of growth focus was was in our are our effectiveness our spend. initiatives, now core rationalizing proving team final and
for while growth when volumes. sales I’m both and progress proud compared product in over quarter again, revenues XX% to our second XXXX, quarter of the as the decreasing simultaneously our achieving marketing once dropped second and expenses of
a has refresh is containment about commercial cutting the cost and the stress impact always not improving exercise. continue to simply cost It investment. critical be and will I return is been company, that our While on want to to
of commercial effort we channels. year, the other of phase in this into the move providers and the very half second directly reaching is the we’ll physicians multiple strategy The of focus next healthcare on timing intentional. through As
preparing to or expand serial a are slowdown test. use months for summer the We early emerging longitudinal from OvaWatch are of seasonal and as the monitoring
virtual of territory. are month Specific the for a and expansion of the to OBGYN of provider physician creation campaign, high drive field social direct our interaction, efficiently activities media journal include will in-person impact more education healthcare the and capabilities targeted and sales ovarian and content advertisements country of hub our in growth outside that cancer parts sales awareness
and quarters marketing As fourth we and sales in the XXXX. expense increase of third for result, a a expect modest
made has and describe his foundation me our built XX. difficult solid the Scientific capabilities measurable we turn Let down on significant remain contribution operations. He has to announced Chief worked company. professional as scientific step a his Ryan now carry that the a the an as innovation. made our however has team enhance decision improvements vision. expected Dr. tirelessly September to Phan He made to effective to that to week, in tenure. and advisor will Officer company during Phan He’s It’s has Dr. to to Last the
commercially on diagnostic EndoCheck to by blood track and year. to publications, clinical complete We OvaWatch both expect and our our remain path test confident of our test the the longitudinal in remain launch to end forward study
to briefly commercially in about launch each now. two talk OvaWatch the me with was these stages. intention Let programs of developed
launch to time in assessment. was initial OvaWatch phase first a single clinical as point application for The
second longitudinal the monitoring expands of for testing. The phase OvaWatch application
Although, provider be can at and an test monitoring that. of that accepted support publication ordered currently a the appropriate of each additional for for clinical tool effective longitudinal to adoption provide be by adnexal to data clinical we’re the patient, finalizing as clinical for ongoing study OvaWatch determined intervals are drive related to an manuscript It’s masses. may
protein-based of detection in Moving aid blood to on endometriosis. our to first the test generation EndoCheck,
of We’re on track for commercial end launch by the XXXX.
and on track on is we acquisition cohort this are obtain data sufficient clinical complete verification validation, Our step. and for sample important focus to current to
to have we launch EndoCheck other collect that We study that meet secured criteria study from timeline. and us samples clinical our around sites continue meet our our confidence the will world, sources nine for the giving
have year operational of our raise over again sustained used terms in our operations support still while growth. quarter, in we vision. long-term excellence, a million XX% In to We once the cash reduction $X.X strengthening balance recently strategic to completed second equity showing sheet prior decreased representing the an
in quality new addition standard impact We effective a team health, care set to gynecologic capital high and of have prudent standard determined deployment. for to high an industry a
call Torsten? would I for turn performance. over review the financial to to Torsten like our Now a of
